Trevor McMillan | |
---|---|
Vice Chancellor of Keele University | |
Assumed office 2015 | |
Personal details | |
Born | Gateshead, England, UK |
Alma mater | Lancaster University University of London |
Profession | University Vice Chancellor |
Website | https://www.keele.ac.uk/connect/vice-chancellorsoffice/vice-chancellor/ |
Alma mater | Lancaster University University of London |
Scientific career | |
Fields | Radiobiology |
Thesis | (1984) |
Trevor John McMillan OBE FRCR FRSB (born 2 October 1959) is an English radiobiologist who became Vice-Chancellor of Keele University on 10 August 2015. [1] [2]
Born in Gateshead, McMillan was educated at Birtley Lord Lawson Comprehensive School, UK before studying Biological Sciences at Lancaster University, graduating in 1981. He was awarded a PhD in Biophysics at the Institute of Cancer Research, University of London in 1984.
McMillan's early research was carried out at the Institute of Cancer Research/Royal Marsden Hospital and the Imperial Cancer Research Fund. McMillan has published widely on the use of X-rays in radiotherapy and the harmful effects of long wavelength UV radiation in sunlight. In particular his research has examined the role of DNA damage and repair in the efficacy of radiotherapy and the harmful cellular effects of UVA following environmentally relevant exposures. [3]
Before moving to Keele as Deputy Vice-Chancellor and Provost in January 2014, he was at Lancaster University where he had several roles including Dean of the Institute of Environmental and Natural Sciences, Head of the Department of Biological Sciences and finally Pro Vice-Chancellor for Research (2005–2014). During this time he chaired the Research and Enterprise Committee for the 1994 Group of Universities in which he led the publication of “Enterprising Universities - Using the Research Base to add Value to Business”. He also Chaired the Management Committee of the N8 Research Partnership. [4]
On the basis of his research, McMillan has worked on national committees that have examined the harmful effects of radiation in the environment. These included COMARE (Committee on Medical Aspects of Radiation in the Environment) [5] for the Department of Health.
He is currently on the Advisory Group for Ionising Radiation [6] for Public Health England and the Advisory Group for the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Chemical and Radiation Threats and Hazards at Newcastle University. He led the production of the report Circulatory Disease Risk for the AGIR. [7] He has recently (December 2015) been announced as the Knowledge Exchange Framework champion for Higher Education Funding Council for England (HEFCE). [8]
McMillan has been awarded Honorary Fellowship of the Royal College of Radiologists and Honorary Membership of the Royal College of Physicians. He is also a Fellow of the Royal Society of Biology.
He was appointed Officer of the Order of the British Empire (OBE) in the 2022 Birthday Honours for services to higher education. [9]
Radiation therapy or radiotherapy is a treatment using ionizing radiation, generally provided as part of cancer therapy to either kill or control the growth of malignant cells. It is normally delivered by a linear particle accelerator. Radiation therapy may be curative in a number of types of cancer if they are localized to one area of the body, and have not spread to other parts. It may also be used as part of adjuvant therapy, to prevent tumor recurrence after surgery to remove a primary malignant tumor. Radiation therapy is synergistic with chemotherapy, and has been used before, during, and after chemotherapy in susceptible cancers. The subspecialty of oncology concerned with radiotherapy is called radiation oncology. A physician who practices in this subspecialty is a radiation oncologist.
The gray is the unit of ionizing radiation dose in the International System of Units (SI), defined as the absorption of one joule of radiation energy per kilogram of matter.
The linear no-threshold model (LNT) is a dose-response model used in radiation protection to estimate stochastic health effects such as radiation-induced cancer, genetic mutations and teratogenic effects on the human body due to exposure to ionizing radiation. The model assumes a linear relationship between dose and health effects, even for very low doses where biological effects are more difficult to observe. The LNT model implies that all exposure to ionizing radiation is harmful, regardless of how low the dose is, and that the effect is cumulative over lifetime.
Radiosensitivity is the relative susceptibility of cells, tissues, organs or organisms to the harmful effect of ionizing radiation.
M. Krishnan Nair was an Indian oncologist. He was the founding director of the Regional Cancer Centre, Thiruvananthapuram, a director of the S.U.T. Institute of Oncology, and Trivandrum Cancer Center(TCC), part of SUT Royal Hospital in Thiruvananthapuram (Trivandrum) and a professor at the Amrita Institute of Medical Sciences & Research in Kochi. The Government of India awarded him the fourth highest civilian award of the Padma Shri in 2001 for his contributions in the cancer care field.
Chris Brink, CBE, FRSSAf is a South African mathematician and academic. He was the Vice-Chancellor of Newcastle University between 2007 and December 2016.
Sarah C. Darby is Professor of Medical Statistics at the University of Oxford. Her research has focused the beneficial effects of smoking cessation, the risk of lung cancer from residential radon, and treatments for early breast cancer. She is also a Principal Scientist with the Cancer Research UK in the Clinical Trial Service Unit (CTSU) and Epidemiological Studies Unit at the Nuffield Department of Clinical Medicine, at the Radcliffe Infirmary, Oxford.
The European Committee on Radiation Risk (ECRR) is an informal committee formed in 1997 following a meeting by the European Green Party at the European Parliament to review the Council of Europe's directive 96/29Euratom, issued in May of the previous year. ECRR is not a formal scientific advisory committee to the European Commission or to the European Parliament. Its report is published by the Green Audit. Dr. Busby is the secretary of ECRR.
Cobalt therapy is the medical use of gamma rays from the radioisotope cobalt-60 to treat conditions such as cancer. Beginning in the 1950s, cobalt-60 was widely used in external beam radiotherapy (teletherapy) machines, which produced a beam of gamma rays which was directed into the patient's body to kill tumor tissue. Because these "cobalt machines" were expensive and required specialist support, they were often housed in cobalt units. Cobalt therapy was a revolutionary advance in radiotherapy in the post-World War II period but is now being replaced by other technologies such as linear accelerators.
The Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) is a regulatory agency under the Commonwealth of Australia that aims to protect Australian citizens from both ionising and non-ionising radiation. ARPANSA works under the guidance of the Australian Radiation Protection and Nuclear Safety Act of 1998 as the national regulatory body of radiation in Australia, with independent departments within each state and territory that regulate radiation within each of their jurisdictions.
Targeted intra-operative radiotherapy, also known as targeted IORT, is a technique of giving radiotherapy to the tissues surrounding a cancer after its surgical removal, a form of intraoperative radiation therapy. The technique was designed in 1998 at the University College London.
Neva Haites OBE FRSE FMedSci is a scientist and physician who investigates molecular genetics and diseases in humans and specialises in cancer genetics; she has more than 90 publications in genetics concerning inherited predisposition to cancer, retinitis pigmentosa, hereditary motor neuropathy and sensory neuropathy.
The Committee on Medical Aspects of Radiation in the Environment (COMARE) is a UK-wide advisory committee set up by the British government. It was established in 1985.
Ralph R. Weichselbaum is an American physician specializing in radiation oncology, a member of the Institute of Medicine of the National Academy of Sciences, Ludwig professor, He is Daniel K. Ludwig Distinguished Service Professor of Radiation Oncology and Chairman, Department of Radiation and Cellular Oncology, at the University of Chicago Pritzker School of Medicine, and Head of the University of Chicago Center for Radiation Therapy, and the director of the Chicago Tumor Institute. Weichselbaum is also Co- Director of the Ludwig Center for Metastasis Research at the University of Chicago.
Pramod Kumar Julka, is an Indian cancer specialist (oncologist), medical educationist and writer, known for performing the first peripheral blood stem cell transplant following high dose chemotherapy in Metastatic Breast Cancer in India. He was honoured by the Government of India, in 2013, by bestowing on him the Padma Shri, the fourth highest civilian award, for his contributions to the fields of medicine and medical education. The American Society of Clinical Oncology (ASCO) has awarded him by bestowing on him the honorary membership.
Mohan Chandra Pant (1956–2015) was an Indian radiation oncologist, institution builder and the founder vice chancellor of the H. N. B. Uttarakhand Medical Education University, Dehradun. He served as the director of Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, and was the Dean and head of the Radiotherapy Department at the King George's Medical University at the time of his death. He received the Dr. B. C. Roy Award, the highest Indian award in the medical category, from the Medical Council of India in 2005. The Government of India awarded him the fourth highest civilian honour of the Padma Shri, in 2008, for his contributions to medicine.
Malcolm Francis Graham Stevens OBE, FRS is an English chemist and Emeritus professor of the University of Nottingham, having previously worked at Aston University where he developed the cancer drug temozolomide.
Adele Chandler Green is an Australian epidemiological senior scientist at the QIMR Berghofer Medical Research Institute in Brisbane and is the institute's Head of Cancer and Population Studies Group.
Amy Berrington de González is a scientist and Professor of Clinical Epidemiology at the Institute of Cancer Research in London.
Deborah Watkins Bruner is an American researcher, clinical trialist, and academic. She is the senior vice president for research at Emory University. Her research focus is on patient reported outcomes, symptom management across cancer sites, sexuality after cancer treatment, and effectiveness of radiotherapy modalities. Bruner's research has been continually funding since 1998, with total funding of her research exceeding $180 million. She is ranked among the top five percent of all National Institutes of Health-funded investigators worldwide since 2012, according to the Blue Ridge Institute for Medical Research.